Current evidence indicates that drugs commonly used for the treatment of DM, including dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), SGLT-2is and metformin, may influence the progression of SARS-CoV-2 infection. This evidence concerns the gene DPP4 and diabetes mellitus.